Want to see JP:4594 full AI Analyst Report?
BrightPath Biotherapeutics Co.Ltd. (4594) AI Stock Analysis
BrightPath Biotherapeutics Co.Ltd.
(TSE/TYO:4594)
The overall score is very low, reflecting significant fundamental and technical headwinds. The company's financial health is poor due to minimal revenue and high cash burn, despite a debt-free balance sheet. Technicals confirm strong bearish momentum with the stock trading well below all major moving averages. The negative P/E ratio further underscores the lack of profitability. The primary risk is the company's ability to fund operations before achieving a commercial milestone.
BrightPath Biotherapeutics Co.Ltd. (4594) vs. iShares MSCI Japan ETF (EWJ)
- Market Cap
- JPY 5.56B
- Dividend Yield
- ―
- Average Volume (3M)
- 1.32M
- Price to Earnings (P/E)
- -3.1
- Beta (1Y)
- 0.78
- Revenue Growth
- -94.55%
- EPS Growth
- -6.51%
- Country
- Japan
- Employees
- 42
- Sector
- General
- Sector Strength
- 55
- Industry
- Biotechnology
BrightPath Biotherapeutics Co.Ltd. Business Overview & Revenue Model
Company Description
BrightPath Biotherapeutics Co., Ltd. specializes in the development of innovative cancer immunotherapies. Among its leading candidates is GRN-1201, currently undergoing Phase II clinical studies for non-small cell lung cancer and Phase I studies for...
BrightPath Biotherapeutics Co.Ltd. Financial Statement Overview
Summary
Financial performance is weak, driven by deeply negative income and cash flow scores. The company has minimal revenue, substantial operating losses, and heavy cash burn. The balance sheet is the only positive, with no debt and a strong equity base, but this is overshadowed by the unsustainable burn rate.
Income Statement
12Very NegativeBalance Sheet
65PositiveCash Flow
15Very Negative| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 84.00K | 84.00K | 1.13M | 72.00K | 5.28M | 15.41M |
| Gross Profit | 55.00K | 55.00K | 1.10M | -341.00K | -13.33M | -23.03M |
| EBITDA | -1.30B | -1.30B | -1.15B | -1.17B | -1.47B | -1.45B |
| Net Income | -1.30B | -1.30B | -1.15B | -1.17B | -1.49B | -1.48B |
Balance Sheet | ||||||
| Total Assets | 2.60B | 2.60B | 1.12B | 1.23B | 1.70B | 2.77B |
| Cash, Cash Equivalents and Short-Term Investments | 2.16B | 2.16B | 810.47M | 1.06B | 1.53B | 2.31B |
| Total Debt | 0 | 0 | 25.00M | 112.50M | 0 | 87.50M |
| Total Liabilities | 236.41M | 236.41M | 195.62M | 251.27M | 133.91M | 239.73M |
| Stockholders Equity | 2.37B | 2.37B | 924.99M | 978.99M | 1.57B | 2.53B |
Cash Flow | ||||||
| Free Cash Flow | 0 | -1.37B | -1.25B | -1.16B | -1.21B | -1.53B |
| Operating Cash Flow | 0 | -1.37B | -1.25B | -1.16B | -1.20B | -1.51B |
| Investing Cash Flow | 0 | -1.93M | -1.37M | -7.65M | -1.76M | -17.57M |
| Financing Cash Flow | 0 | 2.71B | 1.00B | 690.96M | 432.10M | 569.23M |
BrightPath Biotherapeutics Co.Ltd. Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4594, the sentiment is Negative. The current price of 40.00 is below the 20-day moving average (MA) of 42.70, below the 50-day MA of 49.44, and below the 200-day MA of 55.86, indicating a bearish trend. The MACD of -2.74 indicates Negative momentum. The RSI at 33.83 is Neutral, neither overbought nor oversold. The STOCH value of 38.33 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:4594.
BrightPath Biotherapeutics Co.Ltd. Peers Comparison
Overall Rating
JP:709666Neutral
JP:459348Neutral
JP:488045Neutral
JP:459942Neutral- JP:459438Underperform
JP:777637Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| JP:7096 | 66Neutral | JPY 7.18B | 48.11 | ― | ― | 4.85% | -40.57% |
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| JP:4593 | 48Neutral | JPY 37.00B | 55.04 | ― | ― | -47.32% | ― |
| JP:4880 | 45Neutral | JPY 5.68B | 57.55 | ― | 1.75% | -9.94% | ― |
| JP:4599 | 42Neutral | JPY 8.71B | -4.68 | ― | ― | ― | 4.85% |
| JP:4594 | 38Underperform | JPY 5.56B | -3.13 | ― | ― | -94.55% | -6.51% |
| JP:7776 | 37Underperform | JPY 7.43B | -6.49 | ― | ― | -56.16% | 3.12% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| JP:4594 | BrightPath Biotherapeutics Co.Ltd. | 40.00 | -22.00 | -35.48% | |
| JP:4593 | Healios KK | 261.00 | -233.00 | -47.17% | |
| JP:4599 | StemRIM Inc. | 134.00 | -139.00 | -50.92% | |
| JP:4880 | CellSource Co., Ltd. | 283.00 | -228.00 | -44.62% | |
| JP:7096 | StemCell Institute | 682.00 | -128.00 | -15.80% | |
| JP:7776 | CellSeed Inc. | 183.00 | -254.00 | -58.12% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 21, 2026